Coproporphyrine Isomers and Methotrexate Elimination (COMETH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00822432
Recruitment Status : Completed
First Posted : January 14, 2009
Last Update Posted : July 31, 2012
Information provided by (Responsible Party):
Assistance Publique - Hôpitaux de Paris

January 13, 2009
January 14, 2009
July 31, 2012
October 2007
August 2011   (Final data collection date for primary outcome measure)
MTX concentrations [ Time Frame: at the end of MTX infusion and every 24-hours until concentrations reach 0,2µM. ]
Same as current
Complete list of historical versions of study NCT00822432 on Archive Site
  • The UCP I/(I+III) ratio [ Time Frame: before and at the end of MTX infusion and at the end of hospitalisation. ]
  • Five polymorphisms of the ABCC2 gene (-24C/T, 1249G/A, 3563T/A, 4544G/A) [ Time Frame: during the study ]
  • Blood cells count . [ Time Frame: before MTX infusion and at the end of hospitalisation ]
  • Renal function [ Time Frame: before MTX infusion and at the end of hospitalisation ]
Same as current
Not Provided
Not Provided
Coproporphyrine Isomers and Methotrexate Elimination
Urinary Ratio of the Coproporphyrins Isomers I and III and Its Relationships With Methotrexate Elimination in Patients With a Lymphoid Malignancy
High dose methotrexate (MTX) is responsible of severe toxicity in patients in whom elimination from plasma is delayed. Factors responsible for MTX accumulation are partly known but some patients still experience toxicity despite adequate measures being taken. Our hypothesis is that renal tubular secretion may be impaired in these patients. This study aims at evaluating the performance of the UCP ratio (urinary ratio of coproporphyrins), a putative biomarker of tubular secretion, in predicting delayed MTX elimination.
MTX is a substrate of MRP2, a renal tubular transporter encoded by the ABCC2 gene. It has been shown that single nucleotide polymorphisms (SNPs) on the ABCC2 gene are associated with impairment of MTX elimination. Mutations on the ABCC2 gene are also responsible for the Dubin-Johnson syndrome, characterised by the absence of a functional MRP2 protein. Apart from hyperbilirubinaemia, the main biological perturbation observed in this disease is a typical increase of the urinary ratio of coproporphyrins I (I+ III) (UCP ratio). Our hypothesis is that the UCP ratio could be used as a biomarker of MRP2's activity, thus predicting MTX elimination. One hundred patients treated with high dose MTX will be recruited in this prospective study. Their UCP ratio will be measured before and after MTX administration and correlated with MTX clearance. A genetic analysis will be conducted to study the five more frequents SNPs of ABCC2 in each patient.
Time Perspective: Cross-Sectional
Not Provided
Retention:   Samples With DNA
Non-Probability Sample
  • Patients aged more than 18 y, hospitalized in the neurology or in the haematology department at PSP hospital of Paris or in the haematology department at CHU of Tours
  • Who should receive high-dose methotrexate (> 1 g/m2) for one of the following conditions : Central Nervous System Neoplasms; Lymphoma, Large B-Cell, Diffuse; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma or Burkitt lymphoma
  • Central Nervous System Neoplasms
  • Lymphoma, Large B-Cell, Diffuse
  • Precursor B-Cell Lymphoblastic Leukemia-Lymphoma
  • Burkitt Lymphoma
Not Provided
Benz-de Bretagne I, Zahr N, Le Gouge A, Hulot JS, Houillier C, Hoang-Xuan K, Gyan E, Lissandre S, Choquet S, Le Guellec C. Urinary coproporphyrin I/(I + III) ratio as a surrogate for MRP2 or other transporter activities involved in methotrexate clearance. Br J Clin Pharmacol. 2014 Aug;78(2):329-42. doi: 10.1111/bcp.12326.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2011
August 2011   (Final data collection date for primary outcome measure)

Inclusion criteria :

  • Patients receiving HDMTX (≥1g/m2) for a primitive cerebral lymphoma, a large cell lymphoma, a lymphoblastic lymphoma, a Burkitt's lymphoma or an acute lymphoblastic leukaemia,
  • over 18 years old,
  • Signed informed consent.
  • Affiliated to a medical assurance.
  • Able to respect the protocol.
  • Effective contraception for women.

Exclusion criteria :

  • renal failure,
  • liver failure,
  • hepatic cytolysis,
  • chronic respiratory deficiency,
  • pregnancy,
  • breast-feeding,
  • Concomitant medication: phenytoin, probenecid, trimethoprim, phenylbutazone, salicylates, non steroid anti-inflammatory, yellow fever vaccine.
  • Patient included in another study in the four weeks preceding his inclusion.
Sexes Eligible for Study: All
18 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Assistance Publique - Hôpitaux de Paris
Assistance Publique - Hôpitaux de Paris
Not Provided
Principal Investigator: Chantal Le Guellec, PharmD, PhD CHRU of Tours
Assistance Publique - Hôpitaux de Paris
January 2009